Apellis Says Mixed Phase III Results Position Geographic Atrophy Candidate For Filing

 
• By Joseph Haas

Apellis plans to file pegcetacoplan for approval as the first drug to treat the advanced AMD condition geographic atrophy, despite the C3 inhibitor hitting its endpoint in only one of two pivotal trials.

Eye
Apellis hopes to get the first approval for a geographic atrophy drug

More from Clinical Trials

More from R&D